Clinical trial NCT02251548: A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Official title: A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Chronic Lymphocytic Leukemia
Leukemia
Keywords: Chronic lymphocytic leukemia
Leukemia
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Pharmacyclics LLC.
name: The Leukemia and Lymphoma Society
name: Blood Cancer Research Partnership
First posted: 2014-09-29
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Detailed description: Ibrutinib is a type of drug called a kinase inhibitor. It is believed to block a protein called Bruton's tyrosine kinase (BTK) that helps CLL cells live and grow. By blocking this, it is possible that the study drug will kill cancer cells or stop them from growing. Ibrutinib has been FDA approved for the treatment of CLL patients who have received at least one prior treatment; however, the FDA has not yet approved ibrutinib as the first treatment for previously untreated CLL. Therefore, ibrutinib is still considered to be study drug, which means it is still being studied.

Fludarabine, cyclophosphamide, and rituximab (FCR) are intravenous chemotherapy and antibody drugs that together are a standard chemotherapy regimen used for younger patients with CLL. Although FCR is highly effective, it does not typically lead to cure.

In this research study, the investigators are combining a new treatment for CLL, ibrutinib, with a standard chemotherapy regimen for CLL, FCR, to determine whether this combination (iFCR) is safe and effective for patients with previously untreated CLL.

Eligibility criteria: Inclusion Criteria:

* Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma. as per IW-CLL 2008 criteria. Patients must also require therapy for that diagnosis, based on meeting at least one of the following criteria:
* evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin \<11.0 g/L) and/or thrombocytopenia (platelets \<100 x 10\^9/L)
* massive (≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly
* massive nodes (at least 10 cm longest diameter), progressive, or symptomatic lymphadenopathy
* progressive lymphocytosis with an increase of more than 50% over a 2-month period or LDT of \<6 months. Lymphocyte doubling time may be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of \<30 x 10\^9/L, LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections) should be excluded
* autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy
* documented constitutional symptoms, defined as 1 or more of the following disease-related symptoms or signs:

  * unintentional weight loss \>10% within 6 months prior to screening
  * significant fatigue (inability to work or perform usual activities)
  * fevers \>100.5° F or 38.0° C for 2 or more weeks prior to screening without evidence of infection
  * night sweats for more than 1 month prior to screening without evidence of infection

    * No prior CLL-directed therapy that was instituted due to patient previously meeting IW-CLL 2008 criteria for treatment
    * Age greater than or equal to 18 years and less than or equal to 65. Because CLL is extremely rare in persons \<18 years of age, children are excluded from this study. Because iFCR is an aggressive therapy that is likely to be less well-tolerated even in fit elderly subjects, persons \> 65 years of age are excluded
    * ECOG performance status ≤ 1
    * Adequate hematologic function independent of growth factor support for at least 7 days prior to screening and randomization, with the exception of pegylated G-CSF (pegfilgrastim) and darbepoetin which cannot be administered within 14 days of screening.
* Patients must meet the following hematologic criteria at screening:

  * Absolute neutrophil count ≥ 750 cells/mm3 (0.75 x 109/L).
  * Platelet count ≥ 50,000 cells/mm3 (50 x 109/L).
  * Hemoglobin ≥ 8 g/L - Adequate hepatic and renal function defined as:
* Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN)

  * Bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
  * Adequate renal function defined by serum creatinine \>1.5 x ULN
  * PT/INR \<1.5 x ULN and PTT (aPTT) \<1.5 x ULN.
  * The effects of ibrutinib on the developing human fetus are unknown. For this reason and because similar agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria:

* Concurrent Conditions:
* History of other malignancies, except:

  * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  * Adequately treated carcinoma in situ without evidence of disease.
* Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of \>20 mg/day of prednisone) within 28 days of the first dose of study drug.
* Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
* Recent infection requiring systemic treatment that was completed ≤ 14 days before the first dose of study drug.
* Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.
* History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
* Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV). Patients who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
* Any uncontrolled active systemic infection.
* Major surgery within 4 weeks of first dose of study drug.
* Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
* Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
* Lactating or pregnant.
* Patients receiving any other study agents
* Patients with known CNS involvement
* Baseline QTcF \>480 ms. NOTE: This criterion does not apply to patients with a left bundle branch block.
* Patients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed after consultation with the Principal Investigator).
* Concurrent administration of medications or foods that are strong inhibitors or inducers of CYP3A
* Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
* Significant co-morbid condition or disease which in the judgment of the Principal Investigator would place the patient at undue risk or interfere with the study
* Unable to receive prophylactic treatment for pneumocystis
* Patients with del(17p) confirmed by FISH in ≥20% of cells or on stimulated karyotype3.2.24 Patients with del(17p) confirmed by FISH in ≥20% of cells or on stimulated karyotype
* Patients with unmutated IGHV who also have a complex karyotype on a stimulated karyotype

Primary outcomes:
measure: Part I: Participants Who Achieve a Minimal Residual Disease (MRD) Negative Complete Response (CR) in the Bone Marrow at 2 Months Post FCR
timeFrame: 2 months after completing combination therapy
measure: Part II: Participants Who Achieve a Minimal Residual Disease (MRD) Negative Complete Response (CR) in the Bone Marrow at 2 Years Post Discontinuation of Ibrutinib After Having Achieved MRD Negative CR at the 2 Months Post FCR Timepoint
timeFrame: 2 years post discontinuation of ibrutinib after 24 months of ibrutinib maintenance
Secondary outcomes:
measure: Overall Response Rate
timeFrame: Response evaluated at 2 months post iFCR. Treatment up to 6 cycles (28 days each).
measure: Complete Response Rate (CRR)
timeFrame: Response evaluated at 2 months post iFCR. Treatment up to 6 cycles (28 days each).
measure: Partial Response Rate (PRR)
timeFrame: Response evaluated at 2 months post iFCR. Treatment up to 6 cycles (28 days each).
measure: Median Progression-Free Survival (PFS)
timeFrame: Disease will be evaluated through imaging cycle 3-6 day 1, and In long-term follow-up, after removal or until participant withdrawal, death, or removal from study. Median follow-up is: 63.24 months (range: 6.83-95.8).
measure: Median Overall Survival (OS)
timeFrame: Median follow-up is: 63.24 months (range: 6.83-95.8).
measure: Rate of MRD Negative CR After 3 Cycles of iFCR
timeFrame: After 3 cycles of iFCR for each patient completing 3 cycles
measure: 1-year Combined Response With MRD From Bone Marrow
timeFrame: at 1 year
measure: Number of Participants Who Convert From Bone Marrow MRD Negative PR to Bone Marrow MRD Negative CR After 1 Year of Ibrutinib Maintenance
timeFrame: 12 months ( 1year) after starting therapy
measure: Number of Participants Who Convert From Bone Marrow MRD Negative PR to Bone Marrow MRD Negative CR After 2 Years on Treatment
timeFrame: 2 years (24 months) from start of therapy
measure: Median Time to Bone Marrow MRD Negativity
timeFrame: Bone marrow biopsies will be performed at baseline, after cycle 3, 2 months post FCR, at 1 year and 2 years of ibrutinib maintenance, and as clinically indicated thereafter
measure: Participants Who Convert From Bone Marrow MRD Negativity to MRD Positivity in Participants Who Discontinue Ibrutinib
timeFrame: Response evaluated at 2 months post iFCR. Treatment up to 6 cycles (28 days each).
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: University of Miami Sylvester Comprehensive Cancer Center
state: Florida
city: Deerfield Beach
country: United States
facility: University of Miami Sylvester Comprehensive Cancer Center
state: Florida
city: Miami
country: United States
facility: Unversity of Miami Sylvester Comprehensve Cancer Center
state: Florida
city: Westwood
country: United States
facility: University of Kansas Cancer Center
state: Kansas
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Kalamazoo
country: United States
facility: West Michigan Cancer Center
state: Michigan
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Matthew Davids, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.